Skip to main content
. 2022 Nov 9;14(22):5493. doi: 10.3390/cancers14225493

Figure 4.

Figure 4

ExLR-based t-signature for the stratification of SCLC. (a) ExLR t-signature scores in chemo-sensitive (N = 33) and chemo-refractory (N = 24) groups. (b) ROC for the performance of the exLR t-signature in predictive chemotherapy treatment sensitivity of SCLC. (c,d) Kaplan–Meier survival analysis (log-rank test) of OS (c) and PFS (d) of SCLC patients with low (n = 28) or high (n = 29) t-scores. (e) Multivariate Cox proportional hazards regression analysis of clinical parameters and t-scores with PFS of SCLC patients. ROC: receiver operating characteristic.